Kalyan R Chitturi1, Ethan A Burns2, Ibrahim N Muhsen3, Kartik Anand4, Barry H Trachtenberg5. 1. Division of Cardiovascular Medicine, Department of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, CE30665201, USA. 2. Houston Methodist Cancer Center, 6445 Main St. Outpatient Center, Floor 24, Houston, TX, 77030, USA. 3. Department of Medicine, Houston Methodist Hospital, Houston, TX, 77030, USA. 4. Great Plains Health Callahan Cancer Center, 601 W Leota St, North Platte, NE, 69101, USA. 5. Methodist DeBakey Heart and Vascular Center, 6400 Fannin St. Suite 3000, Houston, TX, 77030, USA. btrachtenberg@houstonmethodist.org.
Abstract
PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKI) and monoclonal antibodies (mAbs) that target the epidermal growth factor receptor (EGFR) have changed the therapeutic landscape across a range of solid malignancies. However, there is little data regarding the cardiovascular (CV) impact of these agents. The purpose of this review is to discuss reported CV effects, pathophysiology, pre-treatment screening, diagnostic workup, and treatment recommendations in this patient population. RECENT FINDINGS: It is apparent that CV events are not class dependent, and while infrequently reported in clinical trials, unique CV toxicity may occur with EGFR inhibitors, including structural, electrical, and vascular events. There remains an unmet need to fully elucidate the spectrum of CV events associated with EGFR inhibitors. Early CV screening, close clinical monitoring, coupled with a multidisciplinary approach between medical and cardio-oncology is needed to minimize the potentially detrimental impact of cardiotoxicity in this patient population.
PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKI) and monoclonal antibodies (mAbs) that target the epidermal growth factor receptor (EGFR) have changed the therapeutic landscape across a range of solid malignancies. However, there is little data regarding the cardiovascular (CV) impact of these agents. The purpose of this review is to discuss reported CV effects, pathophysiology, pre-treatment screening, diagnostic workup, and treatment recommendations in this patient population. RECENT FINDINGS: It is apparent that CV events are not class dependent, and while infrequently reported in clinical trials, unique CV toxicity may occur with EGFR inhibitors, including structural, electrical, and vascular events. There remains an unmet need to fully elucidate the spectrum of CV events associated with EGFR inhibitors. Early CV screening, close clinical monitoring, coupled with a multidisciplinary approach between medical and cardio-oncology is needed to minimize the potentially detrimental impact of cardiotoxicity in this patient population.
Authors: Cemil Ozcelik; Bettina Erdmann; Bernhard Pilz; Nina Wettschureck; Stefan Britsch; Norbert Hübner; Kenneth R Chien; Carmen Birchmeier; Alistair N Garratt Journal: Proc Natl Acad Sci U S A Date: 2002-06-18 Impact factor: 11.205
Authors: Tomoya Kitani; Sang-Ging Ong; Chi Keung Lam; June-Wha Rhee; Joe Z Zhang; Angelos Oikonomopoulos; Ning Ma; Lei Tian; Jaecheol Lee; Melinda L Telli; Ronald M Witteles; Arun Sharma; Nazish Sayed; Joseph C Wu Journal: Circulation Date: 2019-05-21 Impact factor: 29.690